Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.
Male or female, age ≥18 years old
HBV infection or chronic HBV infection untreated or treated with a nucleoside or nucleotide analog
Willing and able to provide written informed consent
Affiliated with a social securityregimen
Co-infection with HCV, HIV or HDV (or HBV for healthy volunteer)
Acute hepatitis in the year preceding recruitment
Other liver diseases : alcohol, obesity (BMI>30), diabetes, metabolic syndrome (dyslipidemia and/or known hypertension) - Underlying immunological or cancerous diseases
Patient with a disability that prevents him/her from fully understanding the requirements of the trial - Patient under court protection, guardianship or curatorship
Single group
blood sample HBV patient
Other interventionDuring a boold sample at only one follow up visit: * 3 tubes EDTA 10 ml per patient * 1 tube "Paxgene" 1ml * 2 dry tube per patient
blood sample healthy volunteers
Other intervention* 3 tubes EDTA ideally age and sex matched to CHB patient. * 1 tube "Paxgene" 1ml * 2 dry tube
RNA sequencing of B cells from CHB patients at different stages, description of their molecular signature
RNA sequencing of NK cells from CHB patients at different stages, description of their molecular signature (protein expression measured by flow cytometry)
Click on the lead sponsor to view all of their trials.
University Hospital, Limoges
Lead sponsor
National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Collaborator
